Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Trial of AAVAnc80-hOTOF Gene Therapy in Individuals With Sensorineural Hearing Loss Due to Otoferlin Gene Mutations

NCT05821959 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT05821959
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05821959 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Trial of AAVAnc80-hOTOF Gene Therapy in Individuals With Sensorineural Hearing Loss Due to Otoferlin Gene Mutations
Lead sponsor
Eli Lilly and Company
Phase
Phase 3
Overall status
Recruiting
Start date
September 15, 2023
Completion date
December 31, 2029
Enrollment
48 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

sensorineural hearing loss, bilateral